Clinical Trial Update: A Proof of Concept Study With 0.5% Roflumilast Cream in Patients With Mild to Moderate Plaque Psoriasis [Phase 2]

View source ↗

Summary

A Phase 2 proof-of-concept study evaluating 0.5% roflumilast cream for mild-to-moderate plaque psoriasis has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Plaque Psoriasis

Drugs mentioned

• Roflumilast Cream 0.5% (roflumilast)

Snippet

Sponsor: AstraZeneca | Conditions: Plaque Psoriasis | Phase 2 | Status: WITHDRAWN